Tyra biosciences reports first quarter 2025 financial results and highlights

- beach301 study of tyra-300 for pediatric achondroplasia (ach) open for enrollment - - initiated patient dosing in surf431 study of tyra-430 for hepatocellular carcinoma (hcc) - - cash, cash equivalents, and marketable securities of $318.9 million at q1 2025; runway through at least 2027 - carlsbad, calif. , may 8, 2025 /prnewswire/ -- tyra biosciences, inc. (nasdaq: tyra), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in fibroblast growth factor receptor (fgfr) biology, today reported financial results for the first quarter ended march 31, 2025, and highlighted recent corporate progress.
TYRA Ratings Summary
TYRA Quant Ranking